Drug Trial Radar · NCT05417789
Study of Emactuzumab for Tenosynovial Giant Cell Tumor (TGCT)
Last checked: Nov 19, 2026Latest source record: Jul 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
128
Planned (sponsor's estimate)
Start
Oct 9, 2024
Primary completion
Dec 23, 2025
Study completion Sep 30, 2030
Sponsor
- Lead sponsor
- SynOx Therapeutics LimitedIndustry
- Sponsor type
- Industry
- First posted
- Jun 14, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, Phase 3, randomised, double-blind, placebo-controlled study, which aims to evaluate the efficacy and safety of the investigational drug emactuzumab for the treatment of patients with localized or diffuse TGCT where surgical removal of the tumor is not viewed as an option. The study consists of two parts. In Part 1, eligible subjects will be assigned in a 2:1 ratio to receive either emactuzumab or matching placebo in a double-blind fashion, that will be administered in total 5 times as an intravenous (i.v.) infusion once every 2 weeks. This will be followed by an observation period of 3 months leading to a total duration of 24 weeks in Part 1. A number of assessments will be carried out during the course of the study, including physical examinations, blood tests, imaging studies, electrocardiograms, and questionnaires. Part 2 is a long-term double-blind follow-up phase of the subjects on emactuzumab or placebo. Subjects assigned to placebo in Part 1 have the option, subject to eligibility, to crossover to receive open-label emactuzumab in Part 2. Subjects assigned to active drug in Part 1 have the option to receive open-label retreatment under certain circumstances.
Conditions
- TGCT
Interventions
EmactuzumabDrug
Emactuzumab administered once every 2 weeks (q2w)
PlaceboDrug
Matching placebo administered once every 2 weeks (q2w)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Response Rate (ORR)Time frame: Day 0 - Day 180 (6 months)
Locations
33 sites in 12 countries. Site status is shown where the registry gives one.
NextGen Oncology
Beverly Hills, California
USC Norris Comprehensive Cancer Center
Los Angeles, California
The Ohio State University
Columbus, Ohio
MD Anderson Cancer Center
Houston, Texas
MedStar Washington Hospital Center
Georgetown, Washington
Cliniques Universitaires Saint-Luc
Woluwe-Saint-Lambert, Brussels Capital, Belgium
Arthur J.E. Child Comprehensive Cancer Centre
Calgary, Alberta, Canada
Princess Margaret Cancer Centre
Toronto, Ontario, Canada
McGill University Health Centre (MUHC)
Montreal, Quebec, Canada
UNICANCER - Centre Oscar Lambret
Lille, France
Institut Curie - Hôpital de Paris
Paris, France
Oncopole Claudius Regaud Oncologie Médicale
Toulouse, France
Institut Bergonie - PPDS
Bordeaux, Gironde, France
Institut de Cancerologie de Ouest - Saint Herblain
Saint-Herblain, Loire-Atlantique, France
AP-HP - Hôpital Cochin - Port-Royal, site Cochin
Paris, Paris, France
Centre Léon Bérard Centre Régional de Lutte Contre Le Cancer Rhône Alpes
Lyon, Rhône, France
IRCCS lstituto Ortopedico Rizzoli
Bologna, Italy
Fondazione IRCCS Istituto Nazionale dei Tumori
Milan, Italy
Fondazione Policlinico Universitario Campus Bio-Medico
Rome, Lazio, Italy
Istituti Fisioterapici Ospitalieri - IRCCS Istituto Nazionale Tumori Regina Elena
Rome, Lazio, Italy
Fondazione del Piemonte per l'Oncologia (IRCCS)
Candiolo, Piedmont, Italy
Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone
Palermo, Sicily, Italy
Leids Universitair Medisch Centrum
Leiden, Netherlands
Seoul National University Hospital
Seoul, South Korea
Hospital de La Santa Creu i Sant Pau
Barcelona, Spain
Hospital Universitario Virgen del Rocio - PPDS
Seville, Spain
Hospital Universitari i Politecnic La Fe de Valencia
Valencia, Spain
Hospital Universitario Fundacion Jimenez Diaz
Zaragoza, Zaragoza, Spain
Skanes Universitetssjukhus Lund
Lund, Skåne County, Sweden
Universitäts Kinderspital Beider Basel (UKBB)
Basel, Switzerland
Taipei Veterans General Hospital
Taipei, Taiwan
St James's University Hospital
Leeds, United Kingdom
University College Hospital
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.